myelodysplastic syndromes

Summary

Summary: Conditions in which the bone marrow shows qualitative and quantitative changes suggestive of a preleukemic process, but having a chronic course that does not necessarily terminate as acute leukemia.

Top Publications

  1. doi The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
  2. doi Frequent pathway mutations of splicing machinery in myelodysplasia
    Kenichi Yoshida
    Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Nature 478:64-9. 2011
  3. doi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
  4. doi Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Pierre Fenaux
    Hopital Avicenne, Universite Paris XIII, Bobigny, France
    Lancet Oncol 10:223-32. 2009
  5. pmc Clinical effect of point mutations in myelodysplastic syndromes
    Rafael Bejar
    Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 364:2496-506. 2011
  6. pmc Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
    M J Walter
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, MO 63110, USA
    Leukemia 25:1153-8. 2011
  7. doi Unraveling the molecular pathophysiology of myelodysplastic syndromes
    Rafael Bejar
    Brigham and Women s Hospital, Karp Research Building, CHRB 05 211, 1 Blackfan Cir, Boston, MA 02115, USA
    J Clin Oncol 29:504-15. 2011
  8. doi Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
    Gorica Nikoloski
    Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Nat Genet 42:665-7. 2010
  9. pmc Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
    Timothy A Graubert
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri, USA
    Nat Genet 44:53-7. 2012
  10. ncbi Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006

Detail Information

Publications316 found, 100 shown here

  1. doi The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
    ....
  2. doi Frequent pathway mutations of splicing machinery in myelodysplasia
    Kenichi Yoshida
    Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Nature 478:64-9. 2011
    b>Myelodysplastic syndromes and related disorders (myelodysplasia) are a heterogeneous group of myeloid neoplasms showing deregulated blood cell production with evidence of myeloid dysplasia and a predisposition to acute myeloid leukaemia, ..
  3. doi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
    The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined.
  4. doi Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Pierre Fenaux
    Hopital Avicenne, Universite Paris XIII, Bobigny, France
    Lancet Oncol 10:223-32. 2009
    Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage...
  5. pmc Clinical effect of point mutations in myelodysplastic syndromes
    Rafael Bejar
    Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 364:2496-506. 2011
    b>Myelodysplastic syndromes are clinically heterogeneous disorders characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood cytopenias, and a risk of progression to acute myeloid leukemia...
  6. pmc Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
    M J Walter
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, MO 63110, USA
    Leukemia 25:1153-8. 2011
    Alterations in DNA methylation have been implicated in the pathogenesis of myelodysplastic syndromes (MDS), although the underlying mechanism remains largely unknown...
  7. doi Unraveling the molecular pathophysiology of myelodysplastic syndromes
    Rafael Bejar
    Brigham and Women s Hospital, Karp Research Building, CHRB 05 211, 1 Blackfan Cir, Boston, MA 02115, USA
    J Clin Oncol 29:504-15. 2011
    Somatically acquired genetic abnormalities lead to the salient features that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripheral cytopenias, and risk of progression to acute myeloid leukemia...
  8. doi Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
    Gorica Nikoloski
    Department of Laboratory Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Nat Genet 42:665-7. 2010
    In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that EZH2, located at 7q36...
  9. pmc Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
    Timothy A Graubert
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri, USA
    Nat Genet 44:53-7. 2012
    b>Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML)...
  10. ncbi Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1794-803. 2006
    Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy...
  11. doi Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
    R Itzykson
    Service d Hématologie Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris AP HP, Universite Paris 13, Bobigny, France
    Leukemia 25:1147-52. 2011
    ..Response duration and overall survival were, however, comparable in the MUT and WT groups. In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA, independently of karyotype...
  12. doi Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype
    Daniel T Starczynowski
    British Columbia Cancer Agency Research Centre, Vancouver, British Columbia, Canada
    Nat Med 16:49-58. 2010
    ..Thus, inappropriate activation of innate immune signals in HSPCs phenocopies several clinical features of 5q- syndrome...
  13. doi Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009
    The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal haematological diseases characterized by ineffective haematopoiesis and predisposition to acute myeloid leukaemia (AML). The pathophysiology of MDSs remains unclear...
  14. doi Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Raphael Itzykson
    Clinique Hôpital Avicenne, Assistance Publique Hopitaux de Paris, Paris, France
    Blood 117:403-11. 2011
    ..In conclusion, routine tests can identify subgroups of patients with distinct prognosis with AZA treatment...
  15. doi A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
    Pierre Fenaux
    Hopital Avicenne, Assistance Publique Hopitaux de Paris, Universite Paris XIII, Bobigny, France
    Blood 118:3765-76. 2011
    ..patients with International Prognostic Scoring System Low-/Intermediate-1-risk del5q31 myelodysplastic syndromes. Patients received lenalidomide 10 mg/day on days 1-21 (n = 69) or 5 mg/day on days 1-28 (n = 69) of 28-..
  16. pmc Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
    Hideki Makishima
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Blood 119:3203-10. 2012
    b>Myelodysplastic syndromes (MDSs) are chronic and often progressive myeloid neoplasms associated with remarkable heterogeneity in the histomorphology and clinical course. Various somatic mutations are involved in the pathogenesis of MDS...
  17. ncbi Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
    ..Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible...
  18. pmc Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts
    E Papaemmanuil
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    N Engl J Med 365:1384-95. 2011
    b>Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies.
  19. ncbi Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
    ..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
  20. ncbi Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    Blood 108:419-25. 2006
    The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment...
  21. pmc Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    Ying Jiang
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
    Blood 113:1315-25. 2009
    b>Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML)...
  22. doi Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Blood 119:3578-84. 2012
    Mutations in genes of the splicing machinery have been described recently in myelodysplastic syndromes (MDS)...
  23. pmc Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes
    Dominik Beck
    Bioengineering and Bioinformatics Program, Department of Pathology, The Methodist Hospital Research Institute, Weill Cornell Medical College, Houston, TX, 77030, USA
    BMC Med Genomics 4:19. 2011
    b>Myelodysplastic Syndromes (MDSS) are pre-leukemic disorders with increasing incident rates worldwide, but very limited treatment options...
  24. doi Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
    Frederik Damm
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Blood 119:3211-8. 2012
    ....
  25. doi Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese
    Michael Lubbert
    Albert Ludwigs University, Freiburg, Germany
    J Clin Oncol 29:1987-96. 2011
    ..To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy...
  26. pmc Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes
    Asaka Kondo
    Division of Hematology, Department of Medicine, Nippon Medical School, 1 1 5 Sendagi, Bunkyo ku, Tokyo, Japan
    Blood 116:1124-31. 2010
    During disease progression in myelodysplastic syndromes (MDS), clonal blasts gain a more aggressive nature, whereas nonclonal immune cells become less efficient via an unknown mechanism...
  27. doi TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
    Martin Jadersten
    Center for Experimental Hematology M54, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    J Clin Oncol 29:1971-9. 2011
    To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression.
  28. doi Innate immune signaling in the myelodysplastic syndromes
    Daniel T Starczynowski
    Genome Sciences Centre, British Columbia Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC, Canada
    Hematol Oncol Clin North Am 24:343-59. 2010
    b>Myelodysplastic syndromes (MDS) are heterogeneous clonal hematologic malignancies characterized by cytopenias caused by ineffective hematopoiesis and propensity to progress to acute myeloid leukemia...
  29. doi Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients
    Sergio Matarraz
    Centro de Investigación del Cáncer Instituto de Biología Molecular y Celular del Cáncer CSIC USAL, Servicio General de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
    Cytometry B Clin Cytom 78:154-68. 2010
    A heterogeneous spectrum of immunophenotypic abnormalities have been reported in myelodysplastic syndromes (MDS)...
  30. pmc Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
    Sham Mailankody
    Multiple Myeloma Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 118:4086-92. 2011
    ..51-fold (95% confidence interval: 8.19-15.74) increased risk of acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS); risk was very similar before/after 1995 and 2000, respectively. MGUS patients had an 8.01-fold (5...
  31. pmc Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
    Hagop M Kantarjian
    Leukemia Department, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 116:3163-70. 2010
    ..efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine therapy...
  32. doi Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*
    Valeria Santini
    Azienda Ospedaliera Universitaria Careggi, Florence, Italy
    Eur J Haematol 85:130-8. 2010
    ..We present previously unpublished data from two large phase III trials describing common adverse events (AEs) associated with azacitidine and methods to manage them...
  33. ncbi A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  34. doi Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)
    I Kotsianidis
    Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece
    Leukemia 23:510-8. 2009
    ..In myelodysplastic syndromes (MDS), immune deregulation and autoimmunity in the early stages might lead to ineffective hematopoiesis ..
  35. ncbi Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  36. pmc Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia
    Cynthia L Fisher
    Department of Zoology, University of British Columbia, Vancouver, BC, Canada
    Blood 115:38-46. 2010
    ....
  37. doi CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes
    Leonidas Benetatos
    Department of Hematology, University Hospital of Ioannina, Niarchos Avenue, 45500 Ioannina, Greece
    Leuk Res 34:148-53. 2010
    ..Our findings suggest that these genes are abnormally methylated in AML and MDS patients, and methylation of MEG3 confers worse overall prognosis. The MEG3 methylation status may serve as a useful biomarker in leukemia...
  38. pmc Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
    Julien Rocquain
    Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 10:401. 2010
    ..Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and combination of gene mutated in myeloid malignancies is still a matter of investigation...
  39. pmc MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
    Maria E Figueroa
    Department of Medicine Hematology Oncology Division, Weill Cornell Medical College, New York, NY 10065, USA
    Blood 114:3448-58. 2009
    ..Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors...
  40. ncbi International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report
    Janet D Rowley
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Genes Chromosomes Cancer 33:331-45. 2002
  41. pmc Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
    U Platzbecker
    Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus Technical University of Dresden, Dresden, Germany
    Leukemia 26:381-9. 2012
    ..a sensitive donor chimerism analysis of CD34(+) blood cells to pre-empt relapse in patients with CD34(+) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT)...
  42. doi A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Azra Raza
    Columbia University Medical Center, Milstein Hospital Bldg, 6N 435, 177 Fort Washington Avenue, New York, NY 10032, USA
    Cancer 118:2138-47. 2012
    ..This study evaluated 2 extended dose schedules of oral ezatiostat in 89 heavily pretreated patients with low to intermediate-1 risk myelodysplastic syndrome (MDS)...
  43. pmc Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
    Rafael Bejar
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 30:3376-82. 2012
    A subset of patients with myelodysplastic syndromes (MDS) who are predicted to have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) demonstrate more aggressive disease and shorter overall survival than ..
  44. doi IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
    Shahram Y Kordasti
    Department of Haematological Medicine, King s College London, The Rayne Institute, London, UK
    Br J Haematol 145:64-72. 2009
    ..The 'unfavourable' Th17:Tregs ratio in low risk MDS may explain the higher risk of autoimmunity and the improved response to immune suppression in patients with low risk MDS compared to those with high risk disease...
  45. doi The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
    ..and other cytokines are involved in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), but their prognostic significance in these diseases is unknown...
  46. doi Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
    V Santini
    Functional Unit of Haematology, AOU Careggi, University of Florence, Firenze, Italy
    Leuk Res 34:1576-88. 2010
    ..publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update...
  47. doi Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
    Pierre Fenaux
    Hopital Avicenne, Assistance Publique Hôpitaux de Paris and Paris 13 University, Bobigny, France
    Br J Haematol 149:244-9. 2010
    ..When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients...
  48. pmc DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Semin Hematol 45:23-30. 2008
    ..Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease...
  49. ncbi Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome
    Eleni Thanopoulou
    Terry Fox Laboratory, BC Cancer Agency, 601 West 10th Ave, Vancouver, BC, Canada V5Z 1L3
    Blood 103:4285-93. 2004
    ..the investigation of some human hematopoietic malignancies, but application of this approach to the myelodysplastic syndromes (MDSs) has proven difficult...
  50. pmc Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment
    Tony Navas
    Scios Inc, Fremont, CA, USA
    Leuk Lymphoma 49:1963-75. 2008
    b>Myelodysplastic syndromes (MDS) are common causes of ineffective hematopoiesis and cytopenias in the elderly...
  51. doi Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset
    Claudio Fozza
    Institute of Hematology, University of Sassari, Sassari, Italy
    Exp Hematol 37:947-55. 2009
    Immune dysregulation plays a role in the pathophysiology of myelodysplastic syndromes (MDS), as T-cell clones seem to be involved in the inhibition of hematopoietic precursors...
  52. doi Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Am J Hematol 87:692-701. 2012
    ..MDS occurs more frequently in older male and in individuals with prior exposure to cytotoxic therapy...
  53. doi Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study
    Marcos de Lima
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5420-31. 2010
    ..The authors hypothesized that low-dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination...
  54. pmc Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
    Christopher R Cogle
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610 0278, USA
    Blood 117:7121-5. 2011
    The myelodysplastic syndromes (MDSs) are hematologically diverse hematopoietic stem cell malignancies primarily affecting older individuals. The incidence of MDS in the United States is estimated at 3...
  55. doi Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes
    Kathryn A Kolquist
    Sacred Heart Medical Center, Spokane, WA, USA
    Cancer Genet 204:603-28. 2011
    The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders characterized by ineffective hematopoiesis, cytopenias, and a risk of transformation to acute myeloid leukemia (AML)...
  56. pmc Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model
    Kiran Naqvi
    The University of Texas MD Anderson Cancer, Houston, TX 77030, USA
    J Clin Oncol 29:2240-6. 2011
    ..Patients with cancer often experience comorbidities that may affect their prognosis and outcome. The objective of this study was to determine the effect of comorbidities on the survival of patients with myelodysplastic syndrome (MDS)...
  57. pmc Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
    Luca Malcovati
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy
    Blood 118:6239-46. 2011
    ..Furthermore, SF3B1 mutations are independent predictors of favorable clinical outcome, and their incorporation into stratification systems might improve risk assessment in MDS...
  58. doi Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
    Lewis R Silverman
    Department of Medicine Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer 117:2697-702. 2011
    ....
  59. doi Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
    M Mallo
    Spanish Haematological Cytogenetics Working Group, Faculty of Life Sciences, Department of Cell Biology, Physiology, and Immunology, Autonomous University of Barcelona, Bellaterra, Spain
    Leukemia 25:110-20. 2011
    ....
  60. pmc NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes
    Peter L Greenberg
    Stanford Comprehensive Cancer Center, USA
    J Natl Compr Canc Netw 9:30-56. 2011
    ..116,119,120,128,129) Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials...
  61. pmc Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia
    Christopher N Hahn
    Department of Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia
    Nat Genet 43:1012-7. 2011
    ..Identification of such predisposing genes to familial forms of MDS and AML is critical for more effective diagnosis and prognosis, counseling, selection of related bone marrow transplant donors and development of therapies...
  62. pmc Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase
    Li Zhou
    Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cancer Res 71:955-63. 2011
    Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated...
  63. pmc Hypomethylating agents and other novel strategies in myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, PO Box 301402, Houston, TX 77025, USA
    J Clin Oncol 29:516-23. 2011
    Over the last decade, treatment approaches for patients with myelodysplastic syndromes (MDS) have improved significantly. Treatment of MDS is tailored to the specific risk characteristics of the patient...
  64. ncbi Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements
    Idoya Lahortiga
    Department of Genetics, University of Navarra, Pamplona, Spain
    Genes Chromosomes Cancer 40:179-89. 2004
    ..Our data suggest that a unique mechanism is not likely to be involved in 3q21q26 rearrangements...
  65. ncbi CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
    Shahram Y Kordasti
    Department of Hematological Medicine, King s College London, Rayne Institute, 123 Coldharbour Lane, London, UK
    Blood 110:847-50. 2007
    ..032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease...
  66. pmc IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Haematologica 95:1668-74. 2010
    b>Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders with a high propensity to transform into acute myeloid leukemia...
  67. pmc Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease
    Manuel Aivado
    Proteomics Core and Department of Medical Oncology, Dana Farber Harvard Cancer Center, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 104:1307-12. 2007
    b>Myelodysplastic syndromes (MDS) are among the most frequent hematologic malignancies. Patients have a short survival and often progress to acute myeloid leukemia...
  68. doi Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
    Oliver Goodyear
    CRUK Institute for Cancer Studies, University of Birmingham, Birmingham
    Blood 116:1908-18. 2010
    ..Furthermore, it appears that epigenetic therapies have the capacity to induce a CTL response to MAGE antigens in vivo that may contribute to their clinical activity in AML...
  69. pmc Cytogenetic features in myelodysplastic syndromes
    Detlef Haase
    Department of Hematology and Oncology, Georg August University, Robert Koch Str 40, 37075, Gottingen, Germany
    Ann Hematol 87:515-26. 2008
    b>Myelodysplastic syndromes (MDS) comprise a group of bone marrow diseases characterized by profound heterogeneity in morphologic presentation, clinical course, and cytogenetic features...
  70. doi Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
    John F Seymour
    Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia
    Crit Rev Oncol Hematol 76:218-27. 2010
    ..Given this efficacy and tolerability, AZA should be considered the treatment of choice in patients aged ≥ 75 years with good performance status and higher-risk MDS...
  71. pmc NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia
    Ying Wei Lin
    Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889, USA
    Blood 106:287-95. 2005
    The myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic stem-cell disorders characterized by ineffective hematopoiesis and dysplasia...
  72. pmc Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis
    Timothy A Graubert
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS ONE 4:e4583. 2009
    ..2 are among the most common recurring cytogenetic abnormalities detectable in myelodysplastic syndromes (MDS). Prior genomic studies have suggested that haploinsufficiency of multiple 5q31...
  73. ncbi Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia
    J Pedersen-Bjergaard
    The Chromosome Laboratory, Section of Hematology Oncology, Department of Clinical Genetics, Juliane Marie Center, Copenhagen, Denmark
    Leukemia 20:1943-9. 2006
    ....
  74. ncbi Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Dawn Hershman
    Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 99:196-205. 2007
    ..Although these growth factors support chemotherapy, their long-term safety has not been evaluated. We studied the association between G-CSF use and incidence of leukemia in a population-based sample of breast cancer patients...
  75. ncbi Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
    W T Bellamy
    Department of Pathology, and the Bone Marrow Transplant Program, The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Blood 97:1427-34. 2001
    ....
  76. ncbi Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia
    Jens Pedersen-Bjergaard
    Cytogenetic Laboratory, Section 4052, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
    Blood 99:1909-12. 2002
    ..Recent research suggests that these 2 general types of t-AML can now be subdivided into at least 8 genetic pathways with a different etiology and different biologic characteristics...
  77. doi Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
    Katharina Götze
    III Medizinische Klinik, Technische Universitat Munchen, Ismaningerstrasse 15, Munich, Germany
    Ann Hematol 89:841-50. 2010
    b>Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML)...
  78. doi Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
    Thomas Prebet
    Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    J Clin Oncol 29:3322-7. 2011
    ..The outcome of these patients has not yet been described...
  79. pmc Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
    Guillermo Garcia-Manero
    University of Texas, MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, Houston, TX 77025, USA
    J Clin Oncol 29:2521-7. 2011
    ..safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
  80. pmc NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
    Daniella M B Kerbauy
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, PO Box 19024, Seattle, WA, 98109 1024, USA
    Blood 106:3917-25. 2005
    ..However, the data also suggest that combinations of ATO with agents that interfere with other pathways, such as FLIP autoamplification via NF-kappaB, may have considerable therapeutic activity...
  81. doi Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion
    Pierre Fenaux
    Hopital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France
    Leuk Res 34:1410-6. 2010
    ..in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals...
  82. doi Current and future management options for myelodysplastic syndromes
    Jeffrey Bryan
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 70:1381-94. 2010
    The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease...
  83. ncbi Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation
    R Zeiser
    Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwigs University, Freiburg, Germany
    Leukemia 19:814-21. 2005
    ....
  84. doi Molecular bases of myelodysplastic syndromes: lessons from animal models
    Yukiko Komeno
    Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Cell Physiol 219:529-34. 2009
    ..In this review, we summarize the animal models of MDS and discuss the molecular bases of MDS as well as those of leukemia and myeloproliferative disorders (MPD). J. Cell. Physiol. 219: 529-534, 2009. (c) 2009 Wiley-Liss, Inc...
  85. ncbi A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: Obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomes
    Ruth N MacKinnon
    Victorian Cancer Cytogenetics Service, St Vincent s Hospital Melbourne, Australia
    Genes Chromosomes Cancer 46:27-36. 2007
    The dic(17;20) is a recurrent unbalanced translocation occurring rarely in myelodysplastic syndromes and acute myeloid leukemia...
  86. doi Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
    Amanda F Cashen
    Washington University School of Medicine, St Louis, MO, USA
    J Clin Oncol 28:556-61. 2010
    ..We investigated the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older patients with AML...
  87. ncbi Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop
    Mette K Andersen
    Cytogenetic Laboratory, Section of Hematology Oncology, Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark
    Genes Chromosomes Cancer 33:395-400. 2002
    ..Response rates to intensive chemotherapy in this study were comparable to those of de novo disease...
  88. ncbi Risk factors of myelodysplastic syndromes: a case-control study
    S S Strom
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 19:1912-8. 2005
    Little is known about the etiology of myelodysplastic syndromes (MDS)...
  89. doi Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review
    Paolo Bernasconi
    Division of Haematology, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Br J Haematol 142:695-708. 2008
    The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both hematopoietic stem cell disorders...
  90. pmc Safety and efficacy of azacitidine in myelodysplastic syndromes
    Carlos E Vigil
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Drug Des Devel Ther 4:221-9. 2010
    ..The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed...
  91. doi High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
    Daniel T Starczynowski
    Department of Medical Biophysics, British Columbia Cancer Agency, Vancouver, Canada
    Blood 112:3412-24. 2008
    b>Myelodysplastic syndromes (MDSs) pose an important diagnostic and treatment challenge because of the genetic heterogeneity and poorly understood biology of the disease...
  92. ncbi Occupational exposures and haematological malignancies: overview on human recent data
    Alexis Descatha
    Unité de pathologie professionnelle et de santé au travail, Hôpital R Poincaré, AP HP 92380 Garches, France
    Cancer Causes Control 16:939-53. 2005
    ..Occupational causes of haematological malignancies are relatively uncommon, under-studied and under-identified. They are also often unrecognized by clinicians. This review summarizes the principal epidemiologic studies on this topic...
  93. doi Epidemiology of myelodysplastic syndromes
    Sara S Strom
    Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Semin Hematol 45:8-13. 2008
    b>Myelodysplastic syndromes (MDS) are one of the most common hematological conditions among the elderly. Differences in disease classification and diagnosis have made population-based studies an arduous endeavor...
  94. doi A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome
    Alzbeta Vasikova
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Leuk Res 34:1566-72. 2010
    ..The results suggest that increased cell proliferation and resistance to apoptosis together with a loss of cell cycle control, damaged DNA repair and altered immune response may play an important role in malignant clone expansion in MDS...
  95. pmc Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation
    Marina Bousquet
    Institut National de Santé et de Recherche Médicale, U563, Centre de Physiopathologie de Toulouse Purpan, 31300 Toulouse, France
    J Exp Med 205:2499-506. 2008
    Most chromosomal translocations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) involve oncogenes that are either up-regulated or form part of new chimeric genes...
  96. doi Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions
    Nathalie Douet-Guilbert
    Laboratoire d Histologie, Embryologie et Cytogenetique, Faculte de Medecine et des Sciences de la Sante, Universite de Bretagne Occidentale, Brest, France
    Ann Hematol 87:537-44. 2008
    Deletion of the long arm of chromosome 20 is a recurrent abnormality observed in myelodysplastic syndromes (MDS) and in Philadelphia-chromosome-negative myeloproliferative disorders (MPD)...
  97. ncbi Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk
    Debra A Patt
    Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3871-6. 2007
    ..The purpose of this study was to determine the risk of developing acute myeloid leukemia (AML) after adjuvant chemotherapy for breast cancer in older women...
  98. ncbi Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene
    A Minelli
    Biologia Generale e Genetica Medica, , C.P. 217, I 27100, Pavia, Italy
    Cancer Genet Cytogenet 124:147-51. 2001
    ..We postulate that, in fact, an inherited mutation in any of a group of mutator genes causes familial monosomy 7 also in the absence of a recognized mendelian disease, and that marrow chromosome 7 anomalies, in turn, lead to MDS/AML...
  99. ncbi Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
    Steven D Gore
    The Johns Hopkins Oncology Center, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 8:963-70. 2002
    ..Two patients on the 21/28 schedule developed hematological improvement. Prolonged infusions of PB are well tolerated making this an attractive platform for the clinical investigation of HDAC inhibition...
  100. ncbi Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide
    Claudio Praga
    Centre Oscar Lambret, Lille, France
    J Clin Oncol 23:4179-91. 2005
    ..We reviewed follow-up of patients treated in 19 randomized trials of adjuvant epirubicin in early breast cancer to determine incidence, risk, and risk factors for subsequent acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)...
  101. doi Consensus statement on iron overload in myelodysplastic syndromes
    John M Bennett
    The Myelodysplastic Syndromes Foundation, Crosswicks, New Jersey, USA
    Am J Hematol 83:858-61. 2008
    In May 2005 at the 8th International Symposium on Myelodysplastic Syndromes (MDS), a consensus meeting was held on iron overload in MDS (Seymour, Hematol Oncol Clin 2005; Suppl 1:18-25)...

Research Grants78

  1. NF1 GENE IN MYELOID LEUKEMIA AND CYTOKINE SIGNALING
    DAVID LARGAESPADA; Fiscal Year: 2002
    DESCRIPTION: (adapted from the investigator's abstract) Treatment of childhood myelodysplastic syndromes (MDS) as well as chronic and acute myeloid leukemia (CML and AML) remains disappointing compared with well known advances in the ..
  2. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
  3. Molecular Pathogenesis of MDS and CMML
    Jaroslaw P Maciejewski; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: Myelodysplastic syndromes (MDS) is a heterogeneous group of bone marrow failure states characterized by dysplastic hematopoiesis, ..
  4. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Pearlie K Epling Burnette; Fiscal Year: 2009
    b>Myelodysplastic syndromes (MDS) are characterized by incompetent hematopoiesis that leads to single or multi-lineage peripheral cytopenias with the development of acute myeloid leukemia (AML) in approximately 30-40% of cases...
  5. A mouse model of myelodysplastic syndrome progression and leukemic stem cells
    Yupo Ma; Fiscal Year: 2009
    ..Expiration Date: 04/30/2008 Principal Investigator/Program Director (Last, first, middle): Ma, Yupo Myelodysplastic syndromes (MDS) are stem-cell malignancies most frequently seen among elderly patients, resulting in a high annual ..
  6. MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
    Edward Newman; Fiscal Year: 2001
    ..in the treatment of acute myeloid leukemia and likely therapeutic utility in other leukemias and myelodysplastic syndromes. After incorporation into DNA, DAC inhibits the enzyme DNA (cytosine-5)-methyltransferase (MT'ase)...
  7. New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
    Elihu Estey; Fiscal Year: 2007
    The incidence of myelodysplastic syndromes (MDS) is likely to increase as the U.S. population ages. Nonetheless, there are no satisfactory treatments...
  8. Cyclin E Regulation in Normal and Neoplastic Hematopoiesis
    ALEXANDER C MINELLA; Fiscal Year: 2010
    ..These features are characteristics of hematopoietic cells of patients with early-stage myelodysplastic syndromes (MDS)...
  9. FMS TRANSFORMATION/CSF-1 RECEPTOR SIGNAL TRANSDUCTION
    Martine Roussel; Fiscal Year: 1993
    ..human FMS might contribute to the etiology of myeloid proliferative disorders, including leukemias and myelodysplastic syndromes, but no bona fide activating mutations at codon 301 have thus far been identified...
  10. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    SETH JOEL COREY; Fiscal Year: 2010
    b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
  11. The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
    Zhijian Qian; Fiscal Year: 2010
    ..The myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells (HSCs), characterized by ineffective ..
  12. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    Seth Corey; Fiscal Year: 2006
    b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
  13. Targeted Therapy of Lyn in Myelodysplastic Syndrome
    Seth Corey; Fiscal Year: 2007
    b>Myelodysplastic Syndromes (MDS) are a disorder, increasing in frequency, for which there is poor understanding of its pathophysiology and no curative therapy short of an allogeneic stem cell transplant...
  14. Contribution of the vascular niche to the hematopoietic reconstitution.
    Shahin Rafii; Fiscal Year: 2010
    ..and HSC self-renewal will offer new strategies to treat BM failure states, including aplastic anemia, myelodysplastic syndromes and accelerate BM reconstitution after chemotherapy, irradiation and transplantation...
  15. Clinical Hematology Research Career Development Program (K12)
    Ellis Neufeld; Fiscal Year: 2007
    ..and thalassemia; hemophilia and other hemostatic disorders; venous thromboembolism and thrombophilias; myelodysplastic syndromes and myeloproliferative disorders; transfusion medicine, including unique aspects of pediatric ..
  16. Modeling Multi-step Leukemogenesis in Nf1 and Kras Mutant Mice
    JENNIFER LAUCHLE; Fiscal Year: 2007
    ..In contrast, myelodysplastic syndromes (MDSs) are usually associated with low blood cell counts and aberrant bone marrow morphology, while ..
  17. Bone Marrow Failure Clinical Research Center
    Jaroslaw Maciejewski; Fiscal Year: 2006
    ..cytopenias including large granular lymphocyte leukemia and pure red cell aplasia, and various myelodysplastic syndromes. This application presents a multi-targeted approach to improving the medical therapy for IBMFS&C ..